{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:21:49Z","timestamp":1793931709670,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.chest.2026.04.019","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:51:26Z","timestamp":1777359086000},"page":"689-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eosinophil Counts in Adults With Asthma Treated with Anti-IL-4R\u03b1 Rademikibart"],"prefix":"10.1016","volume":"170","author":[{"given":"Michael E.","family":"Wechsler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Quart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Collazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2026.04.019_bib1","unstructured":"US Centers for Disease Control and Prevention. Asthma data visualizations. US Centers for Disease Control and Prevention website. Accessed May 28, 2026. https:\/\/www.cdc.gov\/asthma\/data-visualizations\/default.htm"},{"issue":"7","key":"10.1016\/j.chest.2026.04.019_bib2","first-page":"825","article-title":"Incremental cost burden among patients with severe uncontrolled asthma in the United States","volume":"29","author":"Burnette","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.1016\/j.chest.2026.04.019_bib3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1513\/AnnalsATS.201703-259OC","article-title":"The economic burden of asthma in the United States, 2008-2013","volume":"15","author":"Nurmagambetov","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"9","key":"10.1016\/j.chest.2026.04.019_bib4","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201901-0016OC","article-title":"The projected economic and health burden of uncontrolled asthma in the United States","volume":"200","author":"Yaghoubi","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2026.04.019_bib5","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/biomedicines9111684","article-title":"Characterization of T2-low and T2-high asthma phenotypes in real-life","volume":"11","author":"Ricciardolo","year":"2021","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.chest.2026.04.019_bib6","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jaip.2020.09.051","article-title":"The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma","volume":"9","author":"Fr\u00f8ssing","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.chest.2026.04.019_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5114\/ceji.2024.141345","article-title":"Biomarkers of type 2 and non-type 2 inflammation in asthma exacerbations","volume":"49","author":"Ali","year":"2024","journal-title":"Cent Eur J Immunol"},{"issue":"5","key":"10.1016\/j.chest.2026.04.019_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.anai.2021.07.010","article-title":"Severe asthma exacerbations in the United States: Incidence, characteristics, predictors, and effects of biologic treatments","volume":"127","author":"Trevor","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.chest.2026.04.019_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/pai.13403","article-title":"Blood eosinophil count as predictor of asthma exacerbation. A meta-analysis","volume":"32","author":"Mallah","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"10.1016\/j.chest.2026.04.019_bib10","doi-asserted-by":"crossref","first-page":"e003129","DOI":"10.1136\/bmjresp-2024-003129","article-title":"The impact of the eosinophil on the risk of acute exacerbation in asthma patients","volume":"12","author":"Chen","year":"2025","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"10.1016\/j.chest.2026.04.019_bib11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jaad.2021.09.050","article-title":"Adverse events associated with dupilumab in the World Health Organization pharmacovigilance database","volume":"86","author":"Bettuzzi","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.chest.2026.04.019_bib12","unstructured":"US Food and Drug Administration. Highlights of prescribing information. US Food and Drug Administration website. Accessed 28 May 28, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761055s064lbl.pdf"},{"issue":"26","key":"10.1016\/j.chest.2026.04.019_bib13","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.chest.2026.04.019_bib14","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.chest.2026.04.019_bib15","first-page":"1743","article-title":"How can dupilumab cause eosinophilic pneumonia?","volume":"12","author":"Kurihara","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.chest.2026.04.019_bib16","article-title":"Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.chest.2026.04.019_bib17","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2024-3-5","article-title":"Severe hypereosinophilia in a patient treated with dupilumab and shift to mepolizumab: the importance of multidisciplinary management. A case report and literature review","volume":"13","author":"Munari","year":"2024","journal-title":"Drugs Context"},{"issue":"1","key":"10.1016\/j.chest.2026.04.019_bib18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaip.2024.09.013","article-title":"Eosinophilia and adverse effects of dupilumab for respiratory indications: a real-world setting","volume":"13","author":"Li","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.chest.2026.04.019_bib19","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1016\/j.jaip.2021.02.042","article-title":"Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.chest.2026.04.019_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/17476348.2022.2090342","article-title":"Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management","volume":"16","author":"Caminati","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.chest.2026.04.019_bib21","article-title":"Dupilumab-induced hyper-eosinophilia: a call for treatment guideline","volume":"209","author":"Tang Taylor","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2026.04.019_bib22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1164\/rccm.202409-1708OC","article-title":"Rademikibart treatment for moderate-to-severe, uncontrolled asthma: a phase 2B randomized trial","volume":"211","author":"Kerwin","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 1","key":"10.1016\/j.chest.2026.04.019_bib23","doi-asserted-by":"crossref","first-page":"A5041","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A5041","article-title":"Rapid improvement in lung function observed with rademikibart in patients with moderate-to-severe uncontrolled asthma","volume":"211","author":"Collazo","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 69","key":"10.1016\/j.chest.2026.04.019_bib24","first-page":"PA2481","article-title":"Rapid and sustained FEV1 improvements with rademikibart in type 2 asthma: impact of eosinophils and FeNO","volume":"66","author":"Collazo","year":"2025","journal-title":"Eur Respir J"},{"issue":"suppl 69","key":"10.1016\/j.chest.2026.04.019_bib25","first-page":"PA2480","article-title":"Rademikibart in moderate-to-severe asthma: Impact of eosinophils and regional differences on response","volume":"66","author":"Collazo","year":"2025","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2026.04.019_bib26","article-title":"Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4R\u03b1, for the treatment of Th2 inflammatory diseases","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci Rep"},{"issue":"suppl 1","key":"10.1016\/j.chest.2026.04.019_bib27","doi-asserted-by":"crossref","first-page":"A1397","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A1397","article-title":"Optimized second-generation IL-4R\u03b1 inhibition: structural and molecular dynamics properties of rademikibart Fab-IL-4R\u03b1 complex","volume":"211","author":"Collazo","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.chest.2026.04.019_bib28","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jid.2025.06.1574","article-title":"Biologic Therapies targeting type 2 signaling in atopic dermatitis: a comparative review of structural and thermodynamic differences in mechanism of action","volume":"145","author":"Bunick","year":"2025","journal-title":"J Invest Dermatol"},{"issue":"13","key":"10.1016\/j.chest.2026.04.019_bib29","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2026.04.019_bib30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.chest.2026.04.019_bib31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"10056","key":"10.1016\/j.chest.2026.04.019_bib32","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.chest.2026.04.019_bib33","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.chest.2026.04.019_bib34","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2026.04.019_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.iac.2007.07.001","article-title":"Cardiovascular manifestations of hypereosinophilic syndromes","volume":"27","author":"Ogbogu","year":"2007","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"10.1016\/j.chest.2026.04.019_bib36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/heartjnl-2020-317202","article-title":"Hypereosinophilic syndrome: considerations for the cardiologist","volume":"108","author":"Bondue","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.chest.2026.04.019_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1635483","article-title":"The role of eosinophils and their activation state in hypereosinophilia-associated heart disease","volume":"16","author":"Sunusi","year":"2025","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.chest.2026.04.019_bib38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/heartjnl-2015-307959","article-title":"Hypereosinophilic syndrome: cardiac diagnosis and management","volume":"102","author":"Mankad","year":"2016","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.chest.2026.04.019_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/00015385.2017.1281546","article-title":"Hypereosinophilic cardiac disease","volume":"72","author":"Filippetti","year":"2017","journal-title":"Acta Cardiol"},{"issue":"163","key":"10.1016\/j.chest.2026.04.019_bib40","doi-asserted-by":"crossref","first-page":"210150","DOI":"10.1183\/16000617.0150-2021","article-title":"Eosinophils and eosinophilic immune dysfunction in health and disease","volume":"31","author":"Jackson","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.chest.2026.04.019_bib41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Investig Allergol Clin Immunol"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226005635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369226005635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:50:36Z","timestamp":1789519836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369226005635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0012369226005635"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2026.04.019","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophil Counts in Adults With Asthma Treated with Anti-IL-4R\u03b1 Rademikibart","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2026.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}